作者
Michael B Atkins, Manuel Hidalgo, Walter M Stadler, Theodore F Logan, Janice P Dutcher, Gary R Hudes, Young Park, Song-Heng Liou, Bonnie Marshall, Joseph P Boni, Gary Dukart, Matthew L Sherman
发表日期
2004/3/1
期刊
Journal of clinical oncology
卷号
22
期号
5
页码范围
909-918
出版商
American Society of Clinical Oncology
简介
Purpose
To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC).
Patients and Methods
Patients (n = 111) were randomly assigned to receive 25, 75, or 250 mg CCI-779 weekly as a 30-minute intravenous infusion. Patients were evaluated for tumor response, time to tumor progression, survival, and adverse events. Blood samples were collected to determine CCI-779 pharmacokinetics.
Results
CCI-779 produced an objective response rate of 7% (one complete response and seven partial responses) and minor responses in 26% of these advanced RCC patients. Median time to tumor progression was 5.8 months and median survival was 15.0 months. The most frequently occurring CCI-779–related adverse events of all …
引用总数
学术搜索中的文章
MB Atkins, M Hidalgo, WM Stadler, TF Logan… - Journal of clinical oncology, 2004